Today we found another interesting IPO in which we decided to | Primor Investment Group

Today we found another interesting IPO in which we decided to take part! Finally an IPO from my favourite niche –– pharma
*not an investment advice

Design Therapeutics –– a company developing new genetic disease treatment. They created their own platform, GeneTAC, which is designed for the treatment of degenerative disorders caused by hereditary extensions and nucleotide repeats. Their products are currently undergoing preclinical trials, while the clinical trials are scheduled for 2022.

Ticker –– DSGN
IPO listing date: 26/03/2021
IPO size: $228 million
Market cap: $1.02 billion
Listing price range: $18 – $20
Underwriters: Goldman Sachs, SVB Leerink, Piper Sandler

Highlights
- This company was created with the mission of being the first fully-integrated genetic drug company in its class.
- They currently have 2 drugs , both are in preclinical stages, for treatment of Friedrich ataxia and myotonic dystrophy type 1
- The global therapeutic market is expected to reach $128.9 billion by 2025
- Even though the revenue isn’t blatant, they are still profitable thanks to generated income from interest and grants from the government.
- The management of the company is very strong, including people with deep experience in this industry.

Downsides
- The company itself admits that investing in it at this stage is a high risk . However, this level of risk is common for this type of IPOs.
- They are at an early stage of development and all of their research programs are still in the preclinical or research stage.
- Their candidate products are based on new technologies, making it difficult to predict the timing, outcomes and costs of developing candidate products, as well as the likelihood of obtaining regulatory approval.

https://www.designtx.com/